MetaVia Inc. (MTVA)

MetaVia's stock (MTVA) has experienced significant volatility, including a substantial price decline and a reverse stock split to maintain Nasdaq compliance. Recent clinical trial progress includes dosing the first patient in a higher-dose Phase 1 study of DA-1726, reporting year-end financial results, securing global patent protection for DA-1726, announcing positive results from the Phase 1 trial of DA-1726, and presenting positive data from the Phase 2a trial of vanoglipel.

Information regarding demand seasonality for MetaVia, Inc.'s products and services is not available. As a clinical-stage biotechnology company, its revenue and financial performance are primarily driven by research and development milestones, clinical trial progress, regulatory approvals, and eventual commercialization of its drug candidates, rather than typical seasonal consumer demand patterns.

MetaVia, Inc. (MTVA) is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Its major product candidates include DA-1726, an oxyntomodulin analogue in Phase 1 clinical trials for obesity and potentially MASH, and Vanoglipel (DA-1241), a GPR119 agonist in Phase 2a clinical trials for MASH and Phase 1 trials for type 2 diabetes.

MetaVia, Inc. is headquartered in Cambridge, Massachusetts, United States. The company is expanding its global patent protection for drug candidates like vanoglipel (DA-1241) and DA-1726, indicating intentions for a broader market reach upon commercialization.

MetaVia's brand reputation has been influenced by positive clinical developments and challenges related to its stock performance. Encouraging clinical trial results and expanding patent protection contribute positively, while the stock price decline and reverse stock split could negatively impact investor confidence.

MetaVia Inc. has a mix of institutional and individual/corporate owners. Institutional owners hold a small percentage of MTVA, while Donga St Co Ltd is the largest individual shareholder. Other notable insiders are also reported.